Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial

BACKGROUND & AIMS: Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation was reported to be safe and had potential therapeutic efficacy. We aim to investigate the safety of HBV...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fanping, Zhao, Jinfang, Tan, Anthony Tanoto, Hu, Wei, Wang, Si-Yu, Jin, Jiehua, Wu, Juan, Li, Yuanyuan, Shi, Lei, Fu, Jun-Liang, Yu, Shuangjie, Shen, Yingjuan, Liu, Limin, Luan, Junqing, Shi, Ming, Xie, Yunbo, Zhou, Chun-Bao, Wong, Regina Wanju, Lu-En, Wai, Koh, Sarene, Bertoletti, Antonio, Wang, Tingting, Zhang, Ji-Yuan, Wang, Fu-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651587/
https://www.ncbi.nlm.nih.gov/pubmed/34850325
http://dx.doi.org/10.1007/s12072-021-10250-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651587/
https://www.ncbi.nlm.nih.gov/pubmed/34850325
http://dx.doi.org/10.1007/s12072-021-10250-2

Ejemplares similares